We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+49.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$459M
AUM Growth
+$82.8M
Cap. Flow
-$20.4M
Cap. Flow %
-4.45%
Top 10 Hldgs %
57.01%
Holding
59
New
13
Increased
17
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$7.18M
2
CMPX icon
Compass Therapeutics
CMPX
+$5.48M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$4.65M
4
NTLA icon
Intellia Therapeutics
NTLA
+$4.33M
5
OCUL icon
Ocular Therapeutix
OCUL
+$4.14M

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$19.5M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$11.1M
3
BHVN icon
Biohaven
BHVN
+$8.56M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$6.33M
5
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$6.13M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Miscellaneous 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$2.38B
$60.5M 13.19%
6,653,138
+583,138
+10% +$4.14M
HROW icon
2
Harrow
HROW
$1.44B
$51.9M 11.3%
3,920,600
+100,600
+3% +$1.07M
TGTX icon
3
TG Therapeutics
TGTX
$8.53B
$34.7M 7.56%
2,280,000
+65,000
+3% +$1.04M
KROS icon
4
Keros Therapeutics
KROS
$223M
$24.3M 5.3%
367,500
+10,000
+3% +$593K
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.75B
$22.3M 4.86%
515,000
-95,000
-16% -$4.16M
CPRX
6
DELISTED
Catalyst Pharmaceutical
CPRX
$16M 3.49%
1,004,355
-252,845
-20% -$3.81M
ARVN icon
7
Arvinas
ARVN
$604M
$13.6M 2.97%
330,000
+66,300
+25% +$2.9M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$3.74B
$13.3M 2.9%
897,000
– –
JSPR icon
9
Jasper Therapeutics
JSPR
$23.3M
$12.8M 2.79%
435,573
+37,039
+9% +$658K
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.8B
$12.1M 2.64%
665,000
-34,000
-5% -$540K
APLT
11
DELISTED
Applied Therapeutics
APLT
$12M 2.62%
1,770,000
+677,500
+62% +$3.04M
FDMT icon
12
4D Molecular Therapeutics
FDMT
$824M
$11M 2.39%
344,123
+35,623
+12% +$909K
CDXS icon
13
Codexis
CDXS
$182M
$10.9M 2.37%
3,120,000
+74,475
+2% +$235K
TARA icon
14
Protara Therapeutics
TARA
$236M
$10.8M 2.35%
2,692,594
– –
SLRN
15
DELISTED
ACELYRIN
SLRN
$10.7M 2.32%
1,580,000
-2,566,138
-62% -$19.5M
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$9B
$9.83M 2.14%
210,000
-97,500
-32% -$3.81M
ETON icon
17
Eton Pharmaceutcials
ETON
$1.79B
$9.17M 2%
2,445,781
-84,106
-3% -$367K
TRVI icon
18
Trevi Therapeutics
TRVI
$2.56B
$9.13M 1.99%
2,645,000
+110,000
+4% +$245K
LYEL icon
19
Lyell Immunopharma
LYEL
$358M
$7.48M 1.63%
+167,750
New +$7.18M
NAMS icon
20
NewAmsterdam Pharma
NAMS
$3.2B
$7.46M 1.63%
315,388
+50,000
+19% +$1.01M
VTYX
21
DELISTED
Ventyx Biosciences
VTYX
$7.07M 1.54%
1,285,000
+145,000
+13% +$663K
NTLA icon
22
Intellia Therapeutics
NTLA
$1.84B
$7.02M 1.53%
255,000
+156,000
+158% +$4.33M
CMPX icon
23
Compass Therapeutics
CMPX
$454M
$6.28M 1.37%
+3,170,000
New +$5.48M
XOMA
24
DELISTED
Xoma
XOMA
$6.01M 1.31%
250,000
– –
LQDA icon
25
Liquidia Corp
LQDA
$6.26B
$5.83M 1.27%
395,000
-50,000
-11% -$695K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2024 Portfolio in Review

As of Q1 2024, Opaleye Management held 59 positions worth $459M, up 22% from $376M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $20.4M in Q1 2024, closing 7 positions and reducing 15 holdings. Its most notable exit was IDEAYA Biosciences, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Lyell Immunopharma worth $7.48M.

  • Opaleye Management's largest Q1 2024 buy was Lyell Immunopharma: 167,750 shares worth $7.48M.
  • Opaleye Management added most to Intellia Therapeutics in Q1 2024, an estimated $4.33M increase.
  • Opaleye Management's biggest Q1 2024 reduction was ACELYRIN, cutting an estimated $19.5M.
  • Opaleye Management fully exited IDEAYA Biosciences in Q1 2024, selling an estimated $11.1M.
  • Opaleye Management's ten largest holdings make up 57% of its $459M portfolio in Q1 2024.
  • Opaleye Management opened 13 new positions and closed 7 in Q1 2024.
  • Opaleye Management's portfolio value rose 22% quarter-over-quarter to $459M.

Based on Opaleye Management's 13F filing for Q1 2024, filed 15 May 2024.